From its recent lofty highs of $120 earlier this year, shares in vaccine and blood product manufacturer CSL Limited (ASX: CSL) have dropped back below $100. With the company’s recent investments in building capacity for the future, CSL appears to be in a solid position.

A number of recent developments have strengthened the investment case, in my opinion, with the recent debt reissue foremost among them. CSL recently launched a US$550 million private placement with a weighted average interest cost of 3%, and an average life of 12.5 years. Even with super-low interest rates globally, CSL’s cost of debt is among the very lowest on the ASX.

This is important because as contributor Regan Pearson illustrated here, a significant chunk of the company’s long term returns have come from (sustainably) high levels of debt.

Building manufacturing capacity

CSL is also developing a number of new facilities to boost the capacity of its business all throughout the supply chain. In addition to new production facilities in several countries, CSL is also expanding its packing facilities as well as its network of plasma collection centres. CSL’s plasma collection network grew by 20% to 140 facilities throughout Europe and the USA in the past year.

All of these developments will improve the company’s ability to maintain supply of its important products, as well as potentially increase efficiency and reduce operating costs. In addition to the ongoing turnaround of the Seqirus vaccine division the continued high spending on Research & Development (R&D) provides additional upside potential over the long term.

CSL is starting to look interesting as its shares drop below $100.

How 1 Man Made 100x His Money After 50

Few know, that as Warren Buffett blew out the candles on his 50th birthday cake, he had just 1% of his current fortune. Think about it: At an age when most give up hope, Buffett was just getting started on the remaining 99% of his fortune. Goes to show you that it's never too late for you to potentially get rich. Which is why we've gathered the strategies we learned from Buffett, distilled them down to 11 simple lessons, and put it in an exclusive report for you to claim. Just click here to learn more about this handy investing guide.

HOT OFF THE PRESSES: Motley Fool’s #1 Dividend Pick for 2017!

With its shares up 155% in just the last five years, this ‘under the radar’ consumer favourite is both a hot growth stock AND our expert’s #1 dividend pick for 2017. Now we’re pulling back the curtain for you... And all you have to do to discover the name, code and a full analysis is enter your email below!

Simply enter your email now to receive your copy of our brand-new FREE report, “The Motley Fool’s Top Dividend Stock for 2017.”

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our https://www.fool.com.au/financial-services-guide">Financial Services Guide (FSG) for more information.

Motley Fool contributor Sean O'Neill has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.